NIDO

What NIDO does

NIDO is an early-stage medical device company developing SEPIA, an Epicardial Ablation Solution targeting ventricular tachycardia (VT). Founded in 2015 and headquartered in Boston, Massachusetts, NIDO operates with a small team of 1-10 employees and is led by CEO Farzad Parsaie. The company's focus is on the cardiac electrophysiology market, specifically developing technology for the surgical/epicardial treatment of ventricular arrhythmias — a clinical problem typically addressed by catheter-based ablation, where an epicardial surgical approach may offer advantages in specific patient subsets.

The company's funding profile is consistent with an early-stage medical device developer: NIDO has secured approximately $2.7 million in disclosed funding across two rounds in February 2017, including a $1.4 million award from the National Institutes of Health (NIH) and a $1.3 million Series 2 round led by Broadview Ventures. Both NIH non-dilutive funding and Broadview Ventures' involvement signal institutional validation of the underlying science and clinical thesis, though the absence of disclosed Series A/B venture rounds or strategic corporate backing suggests NIDO remains in the pre-clinical or early feasibility stage of development.

Given the headcount range (1-10 employees) and the funding scale, NIDO appears to be operating in a lean R&D mode, likely focused on prototype development, animal studies, and initial regulatory planning rather than commercial activity. The company has not disclosed revenue, customers, partnerships with medical centers, or regulatory milestones (FDA submissions, IDE approvals, or CE marks), and management team disclosures beyond the CEO are absent. Note: a large volume of scraped source content associated with the nidosurgical.com domain pertains to an unrelated Bolivian web hosting business (Nemabol / Hosting Bolivia); this material has been excluded from the analytical conclusions about NIDO on the basis of conflict with the first-party firmographic identity, funding records (NIH, Broadview Ventures), and named leadership.

Name

NIDO

Legal name

NEMABOL

Website

https://nidosurgical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

NIDO is an early-stage Boston-based medical device company developing SEPIA, an epicardial ablation solution for ventricular tachycardia (VT). Founded in 2015, the company is led by CEO Farzad Parsaie and has secured NIH and Broadview Ventures funding.

Ownership category

akta.pro rank

Product category

Cardiac Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Electrophysiology Mapping & Ablation Systems (HLAHAFAD)

akta.pro secondary industry

Electrophysiology (Heart Rhythm) (HLAKABAC)

Keywords

• Cardiac ablation devices
• Ventricular tachycardia treatment
• Epicardial ablation system
• Medical device development
• Electrophysiology devices

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Web Hosting Services: Annual subscription-based shared hosting plans and VPS servers providing recurring revenue from storage, bandwidth, and server resources
2. Domain Registration: One-time annual fees for domain name registration across .bo, .com.bo, .net.bo, .org.bo, .com, .net, .org TLDs and specialized Bolivian domains
3. SSL Certificates: Sale of SSL security certificates (basic, wildcard, EV with green bar) providing one-time or annual revenue
4. Email Hosting: Corporate email hosting services including VPS-based email and Google Workspace reselling
5. Reseller Hosting: White-label hosting packages for resellers who want to offer hosting services to their own customers

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

NIDO is a medical device company developing SEPIA, an epicardial ablation solution designed to treat ventricular tachycardia (VT). The device is intended for cardiac electrophysiologists and cardiac surgeons performing ablation procedures on patients with VT, particularly those whose arrhythmogenic substrates cannot be effectively reached via endocardial approaches.

Product overview

Hosting Bolivia (operated by Nemabol SRL) is a Bolivia-based web hosting and domain registration provider offering a tiered portfolio of shared hosting plans (Inicial, MyPE, PyME, Empresa, Gold series), VPS servers (Premium, Gold, Platinum tiers), reseller hosting, SSL certificates, corporate email hosting (including VPS email and Google G Suite), and domain registration/transfer services. The product lineup is organized by business size/scale with pricing in Bolivianos, USD, and EUR. Core offerings include cPanel-based shared hosting, SSD-powered VPS servers with SLA guarantees, and comprehensive domain management for .bo and international TLDs.

Differentiator

Problem solved

Functional benefit

Products and services

• SEPIA Epicardial Ablation Solution

Quantifiable outcome

• 99.9% Uptime Guarantee
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• cPanel/WHMcoreTechnology or IntegrationControl panel software licensing - cPanel provides the web hosting control panel for managing accounts, databases, email, FTP, and statistics included in all hosting plans
• SoftaculouscoreTechnology or IntegrationAuto-installer integration - Softaculous auto-installer enables one-click installation of web applications including WordPress, Joomla, and Drupal
• COMODOcoreTechnology or IntegrationSSL certificate provider - COMODO provides SSL security certificates (basic, wildcard, and EV) offered to customers for website security
• Google WorkspaceminorChannel Partner/ Reseller/ DistributorReseller of Google Workspace (G Suite) - offers Google Apps for Businesses including 30GB storage, Gmail, Drive, and Google applications as part of corporate email solutions
• Banco UnioncoreOthersPrimary banking partner for customer payments - bank account 1-00000-21553173 for business transactions; also accepts Tigo Money payments for customer convenience

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• AtriCure: AtriCure is a medical device company specializing in epicardial and hybrid ablation for atrial fibrillation, with growing activity in VT. Its Isolator Synergy clamp and cryoablation tools directly compete with SEPIA in the epicardial access pathway used in EP labs.
• Adagio Medical: Adagio Medical develops a single-shot cryoablation catheter for VT, including endocardial and epicardial VT indications. It is one of the closest VT-specific ablation competitors to NIDO and a likely clinical benchmark for SEPIA.
• Stereotaxis: Stereotaxis builds robotic magnetic navigation systems used in cardiac ablation procedures, including VT. While non-epicardial focused, it competes for the same EP lab time and physician relationships NIDO is targeting.

Emerging players

• Volta Medical: Volta Medical provides AI-driven decision-support for complex arrhythmia ablation, including VT. Comparable as a small, venture-backed cardiac electrophysiology company using technology to compete in the same procedure space.
• Kardium: Kardium is developing the Globe Mapping and Ablation System for atrial arrhythmias, with potential extension into VT. Comparable as a private, venture-backed ablation-device company targeting complex arrhythmias.
• CathVision: CathVision develops AI-enabled EP mapping systems (e.g., ECGenius) used during ablation. Comparable as a venture-backed, niche electrophysiology company selling adjacent technology into the same VT ablation procedures.

Broad incumbents

• Biosense Webster (Johnson & Johnson): Biosense Webster is the market-leading EP ablation franchise (Carto 3, ThermoCool SmartTouch), the dominant incumbent whose installed base and clinical relationships any new VT ablation entrant must displace.
• Boston Scientific: Boston Scientific's EP portfolio (Rhythmia mapping, IntellaNav ablation catheters, varied VT tools) makes it a direct broad incumbent competitor and a likely strategic acquirer of niche ablation assets like SEPIA.
• Medtronic: Medtronic's cardiac ablation portfolio (DiamondTemp, Cardioblate, cryoablation tools) and integrated CryoConsole/Mapping assets position it as a competitor and potential acquirer of next-generation VT ablation technology.
• Abbott: Abbott's EP business (EnSite X, TactiCath, FlexAbility) is a broad incumbent competitor in cardiac ablation and a strategic acquirer of early-stage ablation and VT assets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/Nido_cardio
• LinkedInlinkedin.com/company/nidocardiovascular

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIDO